Aerie Pharmaceuticals Inc

Aerieā€™s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
Aerie initiates phase IIb glaucoma treatment studyAerie Pharmaceuticals Inc. has announced dosing of the first patients enrolled in its phase IIb study of PG324, a novel fixed-combination treatment for glaucoma or ocular hypertension.